Oral candidiasis

Posaconazole (delayed-release tablets)

An oral delayed-release tablet formulation of posaconazole, which exhibits less variable absorption compared with the oral suspension, is available for prophylaxis of invasive Aspergillus and Candida infection.[17]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Candidiasis (mucocutaneous). 2020 [internet publication]. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/candidiasis-0 ​​[68]Furuno JP, Tallman GB, Noble BN, et al. Clinical outcomes of oral suspension versus delayed-release tablet formulations of posaconazole for prophylaxis of invasive fungal infections. Antimicrob Agents Chemother. 2018 Oct;62(10):e00893-18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153813 http://www.ncbi.nlm.nih.gov/pubmed/30012757?tool=bestpractice.com However, it is unknown whether it is a more effective treatment option for oral candidiasis than the standard oral suspension, and is not routinely recommended as yet.​[17]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Candidiasis (mucocutaneous). 2020 [internet publication]. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/candidiasis-0 ​